To the Editor In their recent article on multigene panel testing for breast cancer, Lu and colleagues1 concluded that there is no association between pathogenic variants in the NF1 gene and breast cancer. Although the authors should be congratulated on their willingness to publish research related to panel testing and its potential identification of new associations of genes with breast or ovarian cancer risk, the results on syndromic associations should be disregarded. No NF1 gene control frequency was provided for the general population, though a variant frequency of approximately 0.15% in women with breast cancer was said to be nonsignificant for the NF1 gene. Another recent article2 also concluded that NF1 variants were not linked to breast cancer risk.